Friday 13 September
Treatment Strategies and Sequencing after ET + CDK4/6I for Patients with ER+/HER2− Advanced Breast Cancer
Friday, 18:00 - 19:30
View the satellite invitation
Saturday 14 September
Maximising the Metastatic Breast Cancer Treatment Paradigm and Looking Ahead
Saturday, 13:00 - 14:30
View the satellite invitation
There Is Another Way: Utilising ADCs to Improve Outcomes in Patients with Triple-Negative and HR+/HER2-Negative mBC
Saturday, 13:00 - 14:30
View the satellite invitation
Sunday 15 September
Staying at the Forefront of HER2- And TROP2-Directed Antibody-Drug Conjugate (ADC) Advances in Breast Cancer
Sunday, 13:00 - 14:30
View the satellite invitation
Monday 16 September
How Can We PI3K the Right Treatment for Every Patient With HR+ Breast Cancer?
Monday, 13:00 - 14:30
View the satellite invitation
Three Moves Ahead: Strategic Sequencing Approaches for Patients With HER2+ MBC
Monday, 13:00 - 14:30
View the satellite invitation
Redefining Care for HR-Positive Metastatic Breast Cancer: How to Navigate Critical Decision Points
Monday, 18:00 - 20:00
View the satellite invitation
Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.